Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.

Background: Acute myeloid leukemia (AML) is a hematologic tumor with poor prognosis and significant clinical heterogeneity. By integrating transcriptomic data, single-cell RNA sequencing data and ...

Dasatinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Small Cell Lung Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. In the ...

In 2021, a new chemotherapy drug, Scemblix (asciminib), was approved for Philadelphia chromosome-positive CML in the chronic phase that has been previously treated with two or more tyrosine kinase ...

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

“What happens with CML is there is a cross of your chromosomes, so there is a cross between chromosome 9 and chromosome 22,” Dr. Eric Winer, clinical director of adult leukemia at Dana-Farber Cancer ...

Chromosome abnormality is the condition in a cell or organism where the number of chromosomes or the structure of any chromosome differs from the normal karyotype. When the variant genotype is not ...